Serum Syndecan-1 Levels and Its Relationship to Disease Activity in Patients with Crohn’s Disease

Abstract EN

Background.

Syndecan-1 (SDC-1), a member of the family of heparan sulfate proteoglycans, plays an important role in the resolution of inflammation.

This study aimed to investigate the relationship between SDC-1 and disease activity in Crohn’s disease (CD).

Methods.

Serum samples of 54 patients with CD and 30 healthy controls were obtained.

First, SDC-1 levels of the CD patients were compared to the control group.

Subsequently, SDC-1 levels were analyzed in patients with CD in active and remission periods.

Finally, SDC-1 efficacy in predicting disease activity was evaluated by performing correlation analysis between SDC-1 and C-reactive protein (CRP) and Crohn’s disease activity index (CDAI).

Results.

SDC-1 level was higher in the CD group (61.9 ± 42.6 ng/mL) compared with the control group (34.1 ± 8.0 ng/mL) p = 0.03 .

SDC-1 levels were higher in active CD patients (97.1 ± 40.3 ng/mL) compared with those in remission (33.7 ± 13.5 ng/mL) p < 0.001 .

A significant positive correlation was found between SDC-1 and CRP ( r = 0.687 , p < 0.001 ) and between SDC-1 and CDAI ( r = 0.747 , p < 0.001 ).

Conclusion.

Serum levels of SDC-1 are higher in CD compared to the normal population and can be an effective marker of disease severity.